HIV: Implication in Burkitt lymphoma

Biopolymers and Cell

Volumn 28, Issue 4, 2012, Pages 285-287

  Tsfasman, T M ^a,b   Klibi, M ^a   Pichugin, A M ^a   Lipinski, M ^a   Vassetzky, Y S ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b MECHNIKOV RESEARCH INSTITUTE FOR VACCINES AND SERA   (Russian Federation)

Author keywords

Burkitt lymphoma; HIV 1; Lymphomagenesis

Indexed keywords

IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN M ANTIBODY; INTERLEUKIN 4; MYC PROTEIN; NEF PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BURKITT LYMPHOMA; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL NUCLEUS; CHROMOSOME 14; CHROMOSOME 2; CHROMOSOME 22; CHROMOSOME 8; DISEASE ASSOCIATION; DNA END JOINING REPAIR; DNA REPAIR; GENE LOCATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; NONHUMAN; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84864409623     PISSN: 02337657     EISSN: 19936842     Source Type: Journal    
DOI: 10.7124/bc.00005B     Document Type: Article

References (27)

1. Bellan C., Lazzi S., De Falco G., Nyongo A., Giordano A., Leoncini L. Burkitt’s lymphoma: new insights into molecular patho-genesis. J. Clin. Pathol. 2003. 56, N 3. P. 188-192.
2. Bibas M., Antinori A. EBV and HIV-related lymphoma. Mediterr. J. Hematol. Infect. Dis. 2009. 1, N 2. e2009032.
3. Engels E. A., Biggar R. J., Hall H. I., Cross H., Crutchfield A., Finch J. L., Grigg R., Hylton T., Pawlish K. S., McNeel T. S., Goedert J. J. Cancer risk in people infected with human immunodeficiency virus in the United States. Int. J. Cancer. 2008. 123, N 1. P. 187-194.
4. Joab I., Triki H., de Saint Martin J., Perricaudet M., Nicolas J. C. Detection of anti-Epstein-Barr virus trans-activator (ZEB-RA) antibodies in sera from patients with human immunodeficiency virus. J. Infect. Dis. 1991. 163, N 1. P. 53-56.
5. Lennette E. T., Busch M. P., Hecht F. M., Levy J. A. Potential herpesvirus interaction during HIV type 1 primary infection. AIDS Res. Hum. Retroviruses. 2005. 21, N 10. P. 869-875.
6. Engels E. A., Pfeiffer R. M., Landgren O., Moore R. D. Immunologic and virologic predictors of AIDS-related non-Hodgkin lymphoma in the highly active antiretroviral therapy era. J. Acquir. Immune Defic. Syndr. 2010. 54, N 1. P. 78-84.
7. Guiguet M., Boue F., Cadranel J., Lang J. M., Rosenthal E., Costagliola D. Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDHANRS CO4): a prospective cohort study. Lancet Oncol. 2009. 10, N 12. P. 1152-1159.
8. Silverberg M. J., Chao C., Leyden W. A., Xu L., Horberg M. A., Klein D., Towner W. J., Dubrow R., Quesenberry C. P. Jr., Neugebauer R. S., Abrams D. I. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol. Biomarkers Prev. 2011. 20, N 12. P. 2551-2559.
9. Grogg K. L., Miller R. F., Dogan A. HIV infection and lymphoma. J. Clin. Pathol. 2007. 60, N12. P. 1365-1372.
10. Janz S. Myc translocations in B cell and plasma cell neoplasms .DNA Repair (Amst). 2006. 5, N 9-10. P. 1213-1224.
11. Nikiforova M. N., Stringer J. R., Blough R., Medvedovic M., Fagin J. A., Nikiforov Y. E. Proximity of chromosomal loci that participate in radiation-induced rearrangements in human cells. Science. 2000. 290, N 5489. P. 138-141.
12. Osborne C. S., Chakalova L., Mitchell J. A., Horton A., Wood A. L., Bolland D. J., Corcoran A. E., Fraser P. Myc dynamically and preferentially relocates to a transcription factory occupied by Igh. PLoS Biol. 2007. 5, N 8. e192.
13. Moir S., Fauci A. S. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J. Allergy Clin. Immunol. 2008. 122, N 1. P. 12-19.
14. Moir S., Fauci A. S. B cells in HIV infection and disease. Nat. Rev. Immunol. 2009. 9, N 4. P. 235-245.
15. Shen X., Tomaras G. D. Alterations of the B-cell response by HIV-1 replication. Curr. HIV/AIDS Rep. 2011. 8, N 1. P. 23-30.
16. Grulich A. E., Wan X., Law M. G., Milliken S. T., Lewis C. R., Garsia R. J., Gold J., Finlayson R. J., Cooper D. A., Kaldor J. M. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin’s lymphoma in people with AIDS. AIDS. 2000. 14, N 2. P. 133-140.
17. Fritsch L., Marechal V., Schneider V., Barthet C., Rozenbaum W., Moisan-Coppey M., Coppey J., Nicolas J. C. Production of HIV-1 by human B cells infected in vitro: characterization of an EBV genome-negative B cell line chronically synthetizing a low level of HIV-1 after infection. Virology. 1998. 244, N 2. P. 542-551.
18. Malaspina A., Moir S., Nickle D. C., Donoghue E. T., Ogwaro K. M., Ehler L. A., Liu S., Mican J. A., Dybul M., Chun T. W., Mullins J. I., Fauci A. S. Human immunodeficiency virus type 1 bound to B cells: relationship to virus replicating in CD4+ T cells and circulating in plasma. J. Virol. 2002. 76, N 17. P. 8855-8863.
19. Moir S., Malaspina A., Li Y., Chun T. W., Lowe T., Adelsberger J., Baseler M., Ehler L. A., Liu S., Davey R. T. Jr., Mican J. A., Fauci A. S. B cells of HIV-1-infected patients bind virions through CD21-complement interactions and transmit infectious virus to activated T cells. J. Exp. Med. 2000. 192, N 5. P. 637-646.
20. Badr G., Borhis G., Treton D., Moog C., Garraud O., Richard Y. HIV type 1 glycoprotein 120 inhibits human B cell chemotaxis to CXC chemokine ligand (CXCL) 12, CC chemokine ligand (CCL) 20, and CCL21. J. Immunol. 2005. 175, N 1. P. 302-310.
21. Debaisieux S., Rayne F., Yezid H., Beaumelle B. The Ins and Outs of HIV-1 Tat. Traffic. 2012. 13, N 3. P. 355-363.
22. Huang L., Li C. J., Pardee A. B. Human immunodeficiency virus type 1 TAT protein activates B lymphocytes. Biochem. Biophys. Res. Commun. 1997. 237, N 2. P. 461-464.
23. Lefevre E. A., Krzysiek R., Loret E. P., Galanaud P., Richard Y. Cutting edge: HIV-1 Tat protein differentially modulates the B cell response of na¿ve, memory, and germinal center B cells. J. Immunol. 1999. 163, N 3. P. 1119-1122.
24. Kundu R. K., Sangiorgi F., Wu L.Y., Pattengale P. K., Hinton D. R., Gill P. S., Maxson R. Expression of the human immunodeficiency virus-Tat gene in lymphoid tissues of transgenic mice is associated with B-cell lymphoma. Blood. 1999. 94, N 1. P. 275-282.
25. Swingler S., Zhou J., Swingler C., Dauphin A., Greenough T., Jolicoeur P., Stevenson M. Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe. 2008. 4, N 1. P. 63-76.
26. Xu W., Santini P. A., Sullivan J. S., He B., Shan M., Ball S. C., Dyer W. B., Ketas T. J., Chadburn A., Cohen-Gould L., Knowles D. M., Chiu A., Sanders R. W., Chen K., Cerutti A. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat. Immunol. 2009. 10, N 9. P. 1008-1017.
27. Qiao X., He B., Chiu A., Knowles D. M., Chadburn A., Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat. Immunol. 2006. 7, N 3. P. 302-310.